缺血/再灌注损伤(IRI)是与各种临床疾病相关的发病率和死亡率的重要因素。包括急性冠脉综合征,中风,和器官移植。在缺血期间,发生了严重的缺氧损伤,导致细胞功能障碍和组织损伤。矛盾的是,再灌注可以通过产生活性氧和诱导炎症级联反应来加剧这种损伤。IRI的广泛临床后遗症需要开发治疗策略以减轻其有害作用。这已成为基础科学和转化科学正在进行的研究工作的基石。这篇综述研究了分子氢在不同器官中对IRI的使用,并探讨了其作用的潜在机制。分子氢是一种具有抗炎作用的选择性抗氧化剂,细胞保护,和信号调制特性。在不同的模型中,它已被证明在减轻IRI方面是有效的,包括心力衰竭,脑中风,移植,和手术干预。氢气通过不同的机制减少IRI,比如抑制氧化应激和炎症,ATP产量的提高,减少钙超载,调节细胞死亡,等。仍需要进一步的研究以将分子氢的使用整合到临床实践中。
Ischemia/reperfusion injury (IRI) represents a significant contributor to morbidity and mortality associated with various clinical conditions, including acute coronary syndrome, stroke, and organ transplantation. During ischemia, a profound hypoxic insult develops, resulting in cellular dysfunction and tissue damage. Paradoxically, reperfusion can exacerbate this injury through the generation of reactive oxygen species and the induction of inflammatory cascades. The extensive clinical sequelae of IRI necessitate the development of therapeutic strategies to mitigate its deleterious effects. This has become a cornerstone of ongoing research efforts in both basic and translational science. This review examines the use of molecular
hydrogen for IRI in different organs and explores the underlying mechanisms of its action. Molecular
hydrogen is a selective antioxidant with anti-inflammatory, cytoprotective, and signal-modulatory properties. It has been shown to be effective at mitigating IRI in different models, including heart failure, cerebral stroke, transplantation, and surgical interventions.
Hydrogen reduces IRI via different mechanisms, like the suppression of oxidative stress and inflammation, the enhancement of ATP production, decreasing calcium overload, regulating cell death, etc. Further research is still needed to integrate the use of molecular
hydrogen into clinical practice.